

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
 Lassa fever		University of Oxford	IAVI		
 MERS	Uvax	IDT Barinthus/ University of Oxford			
 Nipah		PHV	University of Oxford		
 Rift Valley fever	UC Davis Afrigen	Wageningen U.	University of Oxford and KEMRI – Wellcome Trust		
 Chikungunya					Valneva
 COVID-19*					SK Bioscience Moderna Novavax University of Hong Kong Biological E Clover AZ/Oxford
 Broadly protective Betacoronavirus	VIDO IVI consortium Bharat/U Syd/ExcellGene	Panacea/THSTI Intravacc	SK Bioscience		
 Mpox			BioNTech		

(*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

	Preclinical		Phase I	Phase II	Phase IIb/III & III	Registration
 Disease X	Akagera	POP BIO	Centivax	SK Bioscience	Moderna	
	University of Queensland	Gennova*				
	University of Oxford	Emervax				
	Boost Biopharma	HMRI				
	ACM Bio	Imperial				
	IVI consortium	Nagasaki University				
	Sinergium	VitriVax				
		Abera Bioscience				
 Filoviruses	Adaptvac	Public Health Vaccines	University of Oxford/Serum Institute of India			
	Stanford	IAVI, with manufacturing by Hilleman**	Moderna			
	Oxford/ Leipzig/ Moderna	Minapharm				

* Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.

** Hilleman will potentially support other CEPI funded rVSV vaccine candidates in the future.

	DISEASE	DEVELOPER	PHASE	TECHNOLOGY	CEPI FUNDING (IN USD)
	Lassa fever	University of Oxford	Phase I	Viral Vector	Up to \$19 million†
		IAVI	Phase II	Viral Vector	Up to \$64.4 million
	MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to \$47 million†
		IDT	Phase I	Viral vector	Up to \$36 million
		Uvax bio	Preclinical	Protein based	Up to \$2.6 million
	Nipah	University of Oxford	Phase II	Viral Vector	Up to \$19 million†
		PHV	Phase I	Viral vector	Up to \$43.6 million
	Rift Valley fever	UC Davis	Preclinical	Live attenuated	Up to \$40 million
		Wageningen University	Phase I	Live attenuated	Up to \$38.4 million
		University of Oxford and KEMRI – Wellcome Trust	Phase II	Viral Vector	Up to \$3.7 million
		Afrigen	Preclinical	mRNA	Up to \$6.2 million
	Chikungunya	Valneva	Registration	Live attenuated	Up to \$65.9 million
	COVID-19	SK Bioscience	Registration	Protein based	Up to \$210 million
		Biological E	Registration	Protein based	Up to \$14 million
		Moderna	Registration	Protein based	Up to \$1 million
		Clover	Registration	Protein based	Up to \$397.4 million
		University of Hong Kong	Registration	Live attenuated	Up to \$5.4 million
		AZ/University of Oxford	Registration	Viral vector	Up to \$384 million
		Novavax	Registration	Protein based	Up to \$399 million
	Mpox	BioNTech	Phase II	mRNA	Up to \$72 million**

(†) Includes Lassa, MERS and Nipah funding

** Funding is part of a total investment of up to \$90m.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

(##) Includes \$13.38 million for funding a Nipah candidate and \$3.6 for funding for a Rabies candidate/platform optimisation.

	Broadly protective Betacoronavirus	IVI Consortium	Preclinical	mRNA	Up to \$23.9 million
		VIDO	Preclinical	Protein based	Up to \$22 million
		Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to \$19.9 million
		SK Bioscience	Phase I/II	Protein based	Up to \$50 million
		Panacea/THSTI	Preclinical	Protein based	Up to \$12.5 million
		Intravacc	Preclinical	Protein based	Up to \$4.8 million
	Disease X	Abera Bioscience	Preclinical	Protein based	Up to \$1.5 million
		Akagera	Preclinical	mRNA	Up to \$1.5 million
		ACM Bio	Preclinical	mRNA	Up to \$2.9 million
		Boost Biopharma	Preclinical	Protein based	Up to \$5 million
		Centivax	Phase I	mRNA	Up to \$5.0 million
		Emervax	Preclinical	CircRNA	Up to \$2.2 million
		Gennova	Preclinical	mRNA	Up to \$16.98 million##
		HMRI	Preclinical	CircRNA	Up to \$3.8 million
		Imperial College London	Preclinical	SaRNA	Up to \$8.4 million
		IVI, KDCA, ST Pharm, SNU	Preclinical	mRNA	Up to \$16 million
		Moderna	Phase III	mRNA	Up to \$54.3 million
		Nagasaki University	Preclinical	mRNA	Up to \$5 million
		University of Oxford	Preclinical	Viral Vector	Up to \$80 million
		POP BIO	Preclinical	Protein based	Up to \$1.5 million
		University of Queensland	Preclinical	Protein based	Up to \$10.6 million
		Sinergium	Preclinical	mRNA	Up to \$1 million
		SK Bioscience	Phase I/II	mRNA	Up to \$40 million
		VitriVax	Preclinical	Inactivated virus/Protein based	Up to \$5 million



Filoviruses

AdaptVac (Broadly Protective)	Preclinical	Virus-like particle	Up to \$12.4 million
Stanford School of Medicine (Broadly Protective)	Preclinical	Protein nanoparticle	Up to \$18 million
University of Oxford, Leipzig Institute for Drug Discovery, Moderna (Broadly Protective)	Preclinical	Viral vector and mRNA	Up to \$26.7 million
University of Oxford/ Serum Institute of India (Bundibugyo)	Phase I	Viral vector	Up to \$8.6 million
Moderna (Bundibugyo)	Phase I	mRNA	Up to \$50 million
IAVI (Bundibugyo) manufactured by Hilleman Laboratories	Preclinical	Viral vector	Up to \$3.2 million for starter vaccine material + Up to \$8.5 million to Hilleman Laboratories to advance development of rVSV vaccine and manufacture doses for clinical trials*
Public Health Vaccines (Bundibugyo)	Preclinical	Viral vector	Up to \$1.9 million
Minapharm (Bundibugyo)	Preclinical	MVA platform	Up to \$16.5 million